FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
News Medical4d
New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Medscape5d
Warning of Confusion Between Nasal and IV Epinephrine
Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...
EurekAlert!5d
Nasal COVID-19 vaccine based on WashU technology to enter US clinical trials
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Hosted on MSN9d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
healthday18d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
U.S. News & World Report19d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...
Newsweek19d
FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...
CNN19d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Gizmodo19d
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...
Fast Company19d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...